Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.44 |
| ▸ | SRC | P12931 | 2/20 | 0.43 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.42 |
| ▸ | PGR | P06401 | 1/20 | 0.42 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.42 |
| ▸ | AR | P10275 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | HTR2B | P41595 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 4/20 | 0.41 |
| ▸ | MGAM | O43451 | 3/20 | 0.41 |
| ▸ | SI | P14410 | 3/20 | 0.41 |
| ▸ | MGAM2 | Q2M2H8 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 4/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22439464 | 0.89 | MGAM (0.48) | GPR84FFAR1SRCNR3C1PGR | |
| SCHEMBL15149313 | 0.86 | GPR84 (0.48) | GPR84FFAR1SRCNR3C1PGR | |
| SCHEMBL6165214 | 0.84 | GABRA1 (0.39) | GPR84CYP2D6SLC6A2SLC6A4KCNH2 | |
| SCHEMBL17070911 | 0.72 | ALDH1A1 (0.40) | MEN1KMT2AALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL1423010 | 0.70 | BACE1 (0.37) | GAAMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL18364645 | 0.70 | GPR84 (0.62) | GPR84FFAR1SRCNR3C1PGR | |
| SCHEMBL5791060 | 0.69 | KDM4E (0.41) | GPR84SLC6A4HTR2AHTR2CHTR2B | |
| SCHEMBL2071514 | 0.69 | GPR84 (0.49) | GPR84FFAR1SRCNR3C1PGR | |
| SCHEMBL29951612 | 0.69 | GPR84 (0.61) | GPR84FFAR1SRCNR3C1PGR | |
| SCHEMBL13767828 | 0.69 | GPR84 (0.61) | GPR84FFAR1SRCNR3C1PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7863305-B2 | 3-amino-1-arylpropyl indoles as monoamine reuptake inhibitors | ROCHE PALO ALTO LLC (US) | 2011-01-04 | — | — | US | disclosed |
| US-7863305-B2 | 3-amino-1-arylpropyl indoles as monoamine reuptake inhibitors | ROCHE PALO ALTO LLC (US) | 2011-01-04 | — | — | US | disclosed |
| US-7863305-B2 | 3-amino-1-arylpropyl indoles as monoamine reuptake inhibitors | ROCHE PALO ALTO LLC (US) | 2011-01-04 | — | — | US | disclosed |
| EP-1756054-B1 | 3-AMINO-1-ARYLPROPYL INDOLES AS MONOAMINE REUPTAKE INHIBITOR | HOFFMANN LA ROCHE (CH) | 2010-03-31 | — | — | EP | disclosed |
| EP-1756054-B1 | 3-AMINO-1-ARYLPROPYL INDOLES AS MONOAMINE REUPTAKE INHIBITOR | HOFFMANN LA ROCHE (CH) | 2010-03-31 | — | — | EP | disclosed |
| EP-1756054-A1 | 3-AMINO-1-ARYLPROPYL INDOLES AS MONOAMINE REUPTAKE INHIBITOR | F.HOFFMANN-LA ROCHE AG (CH) | 2007-02-28 | — | — | EP | disclosed |
| US-20060025467-A1 | 3-amino-1-arylpropyl indoles as monoamine reuptake inhibitors | ROCHE PALO ALTO LLC | 2006-02-02 | — | — | US | disclosed |
| WO-2005118539-A1 | 3-AMINO-1-ARYLPROPYL INDOLES AS MONOAMINE REUPTAKE INHIBITOR | F.HOFFMANN-LA ROCHE AG (CH) | 2005-12-15 | — | — | WO | disclosed |
| EP-0475755-B1 | 3-Aryl-4(3H)quinazolinone CCK antagonists and pharmaceutical formulations thereof | LILLY CO ELI (US) | 1995-09-27 | — | — | EP | disclosed |
| US-5196427-A | Gastrointestinal and central nervous system disorders; hormone inhibitors | ELI LILLY AND COMPANY (US) | 1993-03-23 | — | — | US | disclosed |
| EP-0475755-A1 | 3-Aryl-4(3H)quinazolinone CCK antagonists and pharmaceutical formulations thereof | ELI LILLY AND COMPANY (US) | 1992-03-18 | — | — | EP | disclosed |
| US-5075313-A | For bindign to cholecystokinin receptors | ELI LILLY AND COMPANY (US) | 1991-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025467-A1 | 3-amino-1-arylpropyl indoles as monoamine reuptake inhibitors | TPH1, HTR1A, HTR3A | GPR84 1328/4885FFAR1 475/4885SRC 1869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.